DOI 10.1016/j.lungcan.2025.108593
Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors.
Аннотация
BACKGROUND
Leptomeningeal metastasis (LM) is a devastating complication of advanced non-small cell lung cancer (NSCLC). Currently, there is no valid data and effective treatment for LM after resistance to third-generation EGFR-TKIs. This study aimed to analyze the genomic profiling and prognostic factors of EGFR-mutant NSCLC-LM after resistance to third-generation EGFR-TKIs.
METHODS
This study included 116 patients with EGFR-mutated NSCLC-LM at the Affiliated Brain Hospital of Nanjing Medical University from January 2021 to January 2024. Circulating tumor DNA from cerebrospinal fluid (CSF) and matched plasma samples were analyzed using next-generation sequencing (NGS). Genomic profiling, clinical features, and prognosis were collected and analyzed.
RESULTS
ctDNA abundance in CSF was higher than in paired plasma samples (0.76 vs 0.21, P < 0.001). Compared to plasma, mutations were more easily detected in CSF, including EGFR mutations (73 % vs. 29 %, P < 0.001), TP53 mutations (61 % vs. 35 %, P<0.001), CDK4_amp (57 % vs 0, P < 0.001), CDKN2A_del (27 % vs. 0, P < 0.001), EGFR_amp (22 % vs. 0, P < 0.001), and CDK12 mutations (12 % vs. 2 %, P = 0.006). Pathway analysis indicates that genes enriched in CSF are altered in multiple oncogenic signaling pathways, including cell cycle (80 % vs 23 %, P < 0.001), KRAS/RAF (27 % vs 8 %, P < 0.001), and WNT (18 % vs 4 %, P = 0.002) pathways. Furthermore, CSF exhibits significantly greater copy number variations (CNVs; P = 0.022) and missense mutations (P = 0.015) compared to plasma. The median intracranial progression-free survival and overall survival after LM diagnosis were 6.60 and 14.42 months, respectively. Multivariate analysis demonstrated that baseline Eastern Cooperative Oncology Group performance status (ECOG PS) 1-2, ≥40 mg pemetrexed per time for IVC, and the combination of furmonertinib and bevacizumab were independent favorable predictors of survival. Finally, we reported a case of LM in which ctDNA dynamic changes in CSF were well consistent with his clinical condition.
CONCLUSIONS
Compared to plasma, CSF ctDNA is more sensitive and specific in detecting somatic mutations and metastasis-related pathways. Good performance status, furmonertinib combined with bevacizumab, and high-dose pemetrexed for IVC can improve the prognosis of NSCLC-LM patients after resistance to third-generation EGFR-TKIs.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.